Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for the hemoglobin disorders.

Derek A Persons1, John F Tisdale

  • 1Department of Hematology/Oncology, Division of Experimental Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA. Derek.persons@stjude.org

Seminars in Hematology
|October 28, 2004
PubMed
Summary

Gene therapy using lentiviral vectors shows promise for treating beta-thalassemia and sickle cell disease by correcting genetic defects in autologous stem cells, offering a potential alternative to current treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

Neurology·2026
Same author

Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques.

Blood advances·2026
Same author

Fetal Hemoglobin Research and Clinical Relevance in Sickle Cell Disease.

Physiology (Bethesda, Md.)·2025
Same author

Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.

Blood advances·2025
Same author

Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Hematopoietic stem cell therapy with gene modification to treat sickle cell disease.

Stem cells translational medicine·2025

Area of Science:

  • Hematology
  • Genetic Medicine
  • Gene Therapy

Background:

  • Beta-thalassemia and sickle cell disease are prevalent monogenic disorders with significant patient morbidity and mortality.
  • Current treatments like allogeneic stem cell transplantation and palliative care have limitations.
  • Genetic manipulation of autologous stem cells presents a promising therapeutic alternative.

Purpose of the Study:

  • To review advances in lentiviral vector-mediated gene therapy for hemoglobin disorders.
  • To evaluate the potential of this approach in preclinical nonhuman primate models.
  • To gather safety and efficacy data for future human clinical trials.

Main Methods:

  • Utilizing lentiviral vectors for high-level expression of complex globin gene cassettes.

Related Experiment Videos

  • Achieving therapeutic correction in murine models of beta-thalassemia and sickle cell anemia.
  • Employing in vivo selection of genetically modified cells.
  • Evaluating efficacy in nonhuman primate autologous transplant models.

    • Main Results:

    • Significant progress in lentiviral vector technology for effective gene transfer.
    • Successful therapeutic correction demonstrated in relevant animal models.
    • Advancements in methods for selecting genetically modified cells in vivo.

    Conclusions:

    • Lentiviral gene therapy is a viable strategy for treating beta-thalassemia and sickle cell disease.
    • Preclinical studies in nonhuman primates are crucial for assessing safety and efficacy before human trials.
    • This approach aims to improve patient outcomes by offering a potentially curative treatment with an acceptable risk-benefit profile.